Resolution to issue 1,236,400 shares of common stock with a payment deadline of April 30, 2026, totaling JPY 1.25 billion. This represents approximately 1.37% dilution of the total issued shares.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexera Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4565-20260415-01.pdf","jir_short_summary":"Resolution to issue 1,236,400 shares of common stock with a payment deadline of April 30, 2026, totaling JPY 1.25 billion. This represents approximately 1.37% dilution of the total issued shares.","jir_summary":"### New Share Issuance through Introduction of Retirement-Type Stock Benefit Trust (J-ESOP)\nNexera Pharma Inc. has decided to issue 1,236,400 shares of common stock with a payment deadline of April 30, 2026, accompanying the introduction of a retirement-type stock benefit trust (J-ESOP) system for domestic employees announced on November 19, 2025. The issuance price is set at 1,011 JPY per share, totaling approximately JPY 1.25 billion. The planned allottee is The Japan Trustee Services Bank, Ltd. (Trust E Account), aiming to provide stock benefits to employees. This issuance represents approximately 1.37% dilution against the total issued shares of 90,496,735 shares, and no additional burden is anticipated.\n\n### New Share Issuance Based on Post-Grant Stock Compensation (RSU) System and Determination of Past Issuance Prices\nAt the same Board of Directors meeting, a resolution was made for new share issuance based on the RSU system for the 26th to 28th issuances, totaling 2,049,962 shares (planned). The payment deadline for the 26th issuance is June 1, 2027, with the issuance price already set at 1,011 JPY per share. The 27th and 28th issuances are scheduled for payment in 2028 and 2029 respectively, with the number of shares and issuance prices delegated to the Representative Executive Officer. The RSU system is introduced as an incentive for officers and qualified employees, with total planned issuances under the stock compensation scheme accounting for approximately 6.95% of total issued shares.","jir_financial_highlights":"Number of New Shares Issued (J-ESOP): 1,236,400 shares (Approximately 1.37% of total issued shares)\nIssuance Price per Share (J-ESOP): 1,011 JPY\/share (Based on Tokyo Stock Exchange closing price)\nTotal Issuance Amount (J-ESOP): 1,250,000,400 JPY (Unknown)\nNumber of New Shares Issued under RSU System (26th to 28th issuance): 2,049,962 shares (including planned) (Approximately 6.95% of total issued shares (entire stock compensation scheme))\nPayment Amount for 26th RSU Issuance: 1,011 JPY\/share (Based on Tokyo Stock Exchange closing price)","jir_category":"","jir_hashtags":"#NexeraPharma, #CapitalPolicy, #NewShareIssuance","jir_key_figures":"J-ESOP New Shares Issued: 1,236,400 shares\nJ-ESOP Issuance Price: 1,011 JPY\/share\nRSU System Planned New Shares Issued (26th to 28th issuance total): 2,049,962 shares","jir_meta_title":"[Nexera Pharma] Resolution on New Share Issuance through Retirement-Type Stock Benefit Trust Introduction | April 2026","jir_meta_description":"Nexera Pharma has decided to issue 1,236,400 new shares in April 2026 accompanying the introduction of the retirement-type stock benefit trust (J-ESOP). The stock compensation through the RSU system will continue, with approximately 8.3% new share issuance relative to total issued shares planned.","jir_og_title":"[Nexera Pharma] Resolution on New Share Issuance through Retirement-Type Stock Benefit Trust Introduction","jir_og_description":"Nexera Pharma will issue 1,236,400 new shares accompanying J-ESOP introduction, strengthening stock compensation through the ongoing RSU system.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-40985","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n